Helicase Venture

Helicase Venture operates as an early-stage venture firm, strategically deploying capital into innovative life sciences and Bio-IT companies. The firm’s core offering involves not just financial investment, typically ranging from $1-5 million in seed and Series A rounds, but also active strategic support and access to extensive scientific networks. This approach is designed to foster growth and accelerate the development of groundbreaking health technologies.

The firm was established in 2018 by Richard Tsai, PhD, its Managing Partner. Dr. Tsai brought a distinguished background to Helicase Venture, having previously served as a Partner at BioEngine Capital, where he led life science investments, and held significant roles in corporate strategy and commercialization at Biogen Idec. His extensive experience across pharmaceutical development, consulting, and venture capital forms the bedrock of the firm’s investment philosophy, identifying promising ventures at their nascent stages.

Helicase Venture partners with early-stage companies, aiming to unlock their full potential and facilitate scientific breakthroughs that positively impact patient care. The firm actively engages with leadership teams, providing guidance through critical developmental stages to ensure innovative therapies and solutions reach patients effectively. Its long-term vision centers on advancing healthcare by backing future leaders in the life sciences and Bio-IT sectors.